- Cloud DX’s (CDX) AcuScreen has shown promising results to screen for tuberculosis in Mozambique
- The AI-based study sought to analyze smartphone audio recordings of patient coughs to diagnose active cases of the disease
- AcuScreen is the smartphone component of the company’s Qualcomm Tricorder XPRIZE-winning vital sign monitor, Vitaliti
- Tuberculosis causes 1.4 million preventable deaths per year
- Cloud DX provides a digital and virtual health care platform for patient remote monitoring, aging in place and hospital-quality post-surgical care
- Cloud DX (CDX) is unchanged trading at $0.19 per share
Cloud DX’s (CDX) AcuScreen has shown promising results to screen for tuberculosis in Mozambique.
The AI-based study sought to analyze smartphone audio recordings of patient coughs to diagnose active cases of the disease.
AcuScreen is the smartphone component of the company’s Qualcomm Tricorder XPRIZE-winning vital sign monitor, Vitaliti.
The trial – entitled “Acoustic analysis of cough as a novel technology for the screening and diagnosis of active pulmonary tuberculosis (TB)” – was funded by the Qualcomm Foundation and the Roddenberry Foundation with support from the University of California, San Diego, and the Instituto Nacional de Saúde.
Preliminary results from the trial, led by Celso Khosa M.D. of the Instituto Nacional de Saúde, were recently presented at the 52nd Union World Conference on Lung Health.
Tuberculosis is the world’s deadliest respiratory infection after COVID, causing 1.4 million deaths annually, though it is entirely treatable and preventable.
Tools such as AcuScreen are in dire need to facilitate systematic and discreet screening in mobile clinics and other in-field uses.
“Our data shows that acoustic cough analysis and symptom detection exceed the World Health Organization requirements for a community-based triage system. Such a tool is essential for low-resource and high-burden areas. I look forward to expanding AcuScreen’s use,” Dr. Khosa said.
Robert Kaul, CEO of Cloud DX, added,
“AcuScreen’s success is a milestone event for technology, healthcare, and society. This is the first Qualcomm Tricorder XPRIZE-winning technology to be validated in the field, showing the path forward for our innovations from concept to commercialization.
More importantly, AcuScreen can help combat the spiralling global tuberculosis crisis. AcuScreen is more accessible and accurate and less expensive than x-ray screening. With a stigmatized illness such as TB, it’s important that any solution be handheld, like AcuScreen, for discretion and privacy. This is a technology that virtually every public health or medical clinic can use in front-line triage to test an estimated 3 million undiagnosed TB patients, and to expedite confirmation tests such as GeneXpert.”
Cloud DX provides a digital and virtual health care platform for patient remote monitoring, ageing in place and hospital-quality post-surgical care.
Cloud DX (CDX) is unchanged trading at $0.19 per share as of 10:55 am ET.
